KEYTRUDA (pembrolizumab) Patient Assistance Program
- Clear & Transparent Pricing — Applying To Merck Directly Is Always Free
- Paperwork, Documentation & Doctor-Coordination Handled For You
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Guidance For Infused Keytruda
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Keytruda (Pembrolizumab) Is FDA-Approved Across More Than 30 Cancer Indications Including Melanoma, Non-Small Cell Lung Cancer, Head And Neck Cancer, Classical Hodgkin Lymphoma, Urothelial Carcinoma, Gastric Cancer, Colorectal Cancer (MSI-H/dMMR), Triple-Negative Breast Cancer, Renal Cell Carcinoma, And Many Others. It Is A PD-1 Checkpoint Inhibitor Given As IV Infusion Every 3 Or 6 Weeks — Or As Keytruda Qlex, The Subcutaneous Injection FDA-Approved In September 2025.
- Without Assistance, Keytruda’s List Price Is $12,272 Per 200 mg Dose (Every 3 Weeks) Or $24,544 Per 400 mg Dose (Every 6 Weeks) — Roughly $213,000 Per Year. What You Actually Pay Depends Almost Entirely On Your Insurance.
- The Merck Patient Assistance Program Provides Keytruda Free Of Charge To Eligible Patients With No Insurance Coverage And Household Income Up To $79,800 (Individual), $108,200 (Couple), Or $165,000 (Family Of Four). One Approval Can Cover Up To A Full Year Of Medication
- There Is No Biosimilar Of Keytruda In The U.S. As Of 2026, So There Is No Cheaper Substitute. Other PD-1/PD-L1 Checkpoint Inhibitors (Opdivo, Tecentriq, Imfinzi, Libtayo, Jemperli) Are Different Drugs With Different Approved Indications — Assistance Programs Are The Realistic Path To Affordability
What Is Keytruda Prescription Assistance Program?
The Keytruda Patient Assistance Program is run by the Merck Patient Assistance Program, Inc., the manufacturer’s charitable program, and provides Keytruda at no medication cost to qualifying patients. It is designed for cancer patients who are uninsured or underinsured, with household income up to $79,800 for individuals, $108,200 for couples, or $165,000 for a family of four — and one approved application can cover up to a year of treatment. Applying directly through the Merck Access Program (855-257-3932, Mon–Fri 8 AM–8 PM ET) is always free. The hard part is everything around the form: eligibility verification, income documentation, oncology coordination, biomarker documentation (PD-L1, MSI-H, TMB depending on indication), prior-authorization records, infusion-center logistics, denial appeals, and renewal deadlines. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Keytruda costs roughly $11,000–$13,500 per dose. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$12,800/dose | Save substantially |
| CVS Pharmacy | ~$13,500/dose | Save substantially |
| Walmart | ~$11,500/dose | Save substantially |
| Costco | ~$11,200/dose | Save substantially |
Specialty Pharmacy | ~$12,000/dose | Save substantially |
Just a heads-up — figures are Merck’s published cost data for the 200 mg every-3-weeks dose and vary by plan. Infused Keytruda is billed under Medicare Part B, so the $2,000 Part D out-of-pocket cap does not apply — a Medigap supplement or Medicare Advantage out-of-pocket maximum is what limits these costs.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Keytruda Prescription Program?
The Patient Assistance Program is free to apply for and provides Keytruda at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Keytruda:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
-
Still $11,000–$13,500 per dose per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Merck publishes clear eligibility rules for free Keytruda through its Patient Assistance Program. You will generally qualify if all of the following are true — and if your situation doesn’t fit neatly, contact AffordMyPrescriptions so we can review your case and determine if you qualify for Keytruda assistance:
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Keytruda Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- Your Household Income Is At Or Below $79,800 (Single), $108,200 (Couple), Or $165,000 (Family Of Four)
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Keytruda:
Keytruda (pembrolizumab) is a humanized monoclonal antibody that blocks PD-1 (programmed cell death protein 1) — a checkpoint receptor on T-cells that, when activated by tumor cells, suppresses anti-tumor immunity. By blocking PD-1, Keytruda “releases the brakes” on the immune system and allows T-cells to attack cancer cells. It is FDA-approved across many cancer types.
How Keytruda Works:
Cancer cells often exploit the body’s immune checkpoints by upregulating PD-L1, which activates PD-1 on T-cells and effectively turns off the immune response against the tumor. Keytruda works as a humanized monoclonal antibody that binds to PD-1 on T-cells, preventing PD-L1 and PD-L2 from activating it. This action releases the brakes on the immune system, allowing T-cells to recognize and attack tumor cells for durable anti-tumor responses. While it can produce long-lasting remissions, responses vary, and biomarkers like PD-L1 expression, MSI-H/dMMR status, or high tumor mutational burden help predict its effectiveness.
Form and use:
Keytruda is administered as an intravenous infusion over about 30 minutes — 200 mg every 3 weeks or 400 mg every 6 weeks for most adult indications; pediatric dosing is weight-based at 2 mg/kg every 3 weeks up to 200 mg. In September 2025, the FDA approved Keytruda Qlex, a subcutaneous version injected in 1–2 minutes and approved across most of the same solid-tumor indications. The 6-week schedule and the subcutaneous option can mean fewer clinic visits and lower facility fees — ask your oncologist which form fits your treatment plan. Treatment generally continues until disease progression, unacceptable toxicity, or up to 24 months in specific indications.
Biosimilar Availability:
As of 2026, there is no biosimilar version of Keytruda available in the United States — key patents run into the late 2020s, and pembrolizumab biosimilars in development are not yet approved. Other PD-1 and PD-L1 checkpoint inhibitors are on the market, including Opdivo, Tecentriq, Imfinzi, Bavencio, Libtayo, and Jemperli, but each carries a different set of FDA-approved indications and none is an interchangeable substitute. Until a biosimilar arrives, assistance programs — not substitution — are the realistic affordability path.
Warnings:
Keytruda carries significant warnings for immune-mediated adverse reactions that can affect nearly any organ system in the body. These reactions include pneumonitis, colitis, hepatitis, nephritis, endocrinopathies, severe dermatologic reactions, myocarditis, and neurological conditions like encephalitis. Additionally, it poses risks for solid organ transplant rejection, infusion reactions, and embryo-fetal toxicity. Complication rates are also higher when Keytruda is combined with CTLA-4 inhibitors like Yervoy.
FAQ (Frequently Asked Questions)
How Much Does Keytruda Cost Without Insurance?
Merck’s list price is $12,272 per 200 mg dose (every 3 weeks) or $24,544 per 400 mg dose (every 6 weeks) — approximately $213,000 per year. Uninsured patients who meet the income limits can receive Keytruda at no medication cost through the Merck Patient Assistance Program; our $69.95 monthly fee covers full advocacy and enrollment management.
What Is A Checkpoint Inhibitor?
Checkpoint inhibitors are immunotherapy drugs that block the “off switches” tumors use to hide from your immune system. Keytruda blocks the PD-1 checkpoint on T-cells, freeing your immune system to recognize and attack cancer cells. Unlike chemotherapy, it targets the immune response rather than the tumor directly, which is why side effects and response patterns are different.
Do I Need Biomarker Testing Before Keytruda?
For many indications, yes. Depending on your cancer type, your oncologist may order PD-L1 expression testing, MSI-H/dMMR testing, or tumor mutational burden (TMB) testing to confirm Keytruda is appropriate and to satisfy insurance or assistance-program documentation requirements. We help make sure this documentation is complete before your application goes in.
How Will I Know If Keytruda Is Working?
Your oncology team monitors response with periodic imaging (CT/PET scans), bloodwork, and symptom review, typically every 6–12 weeks. Immunotherapy responses can take longer to appear than chemotherapy responses, and some patients experience “pseudoprogression” — apparent growth before shrinkage — so don’t panic at a single scan.
What Side Effects Should I Watch For?
Contact your care team promptly about new cough or shortness of breath, diarrhea, severe fatigue, rash, vision changes, or symptoms of hormone gland problems (unusual headaches, dizziness, extreme thirst) — these can signal immune-mediated reactions that are most treatable when caught early. Keytruda’s immune-related side effects can affect nearly any organ system.
Can I Get Keytruda Through The PAP If I Have Medicare?
Usually not directly — the free-drug program requires no insurance coverage for the medicine, and Medicare Part B covers infused Keytruda. But covered isn’t the same as affordable: with traditional Medicare and no supplement, roughly 80% of patients paid $1,300–$2,100 per infusion, and the $2,000 Part D cap does not apply to Part B drugs. Medicare patients who can’t afford treatment should ask the Merck Access Program about their options — our team helps Medicare patients map exactly this.
What If My Application Is Denied?
Denials are usually about documentation, not destiny — missing income proof, an insurance-status mismatch, or incomplete prescriber sections. Applications can be corrected and resubmitted, and exception reviews exist for special circumstances. This is the most common point where patients give up, and where an advocate changes the outcome: we review the denial letter, fix what triggered it, and resubmit on your behalf.
Take Control of Your Medication Costs
If you are struggling with the high cost of Keytruda, our team may be able to help you access assistance programs designed to make brand specialty checkpoint inhibitor immunotherapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.